6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
A clinician-focused review of inclisiran pharmacokinetics, subgroup efficacy data, pharmacogenomic considerations, and dose-adjustment guidance for Black and African ancestry patients receiving Leqvio for LDL-C lowering.
Does Leqvio (inclisiran) require dose adjustments for East Asian patients? We review ORION trial subgroup data, siRNA pharmacology, CYP polymorphism relevance, and BMI-based considerations.
A clinical deep-dive into inclisiran's LDL-lowering efficacy, pharmacogenomics, and dosing considerations in Black and African ancestry patients, with ethnicity-stratified subgroup data from ORION-10, ORION-11, and beyond.
A comprehensive, physician-reviewed look at how inclisiran's safety and efficacy may differ in Black and African ancestry patients, covering pharmacogenomics, ethnicity-stratified ORION trial data, and clinical dosing considerations.
Evidence review of inclisiran efficacy in East Asian populations, covering ORION trial subgroup data, PCSK9 genetic variants, dosing, and pharmacogenomic differences that may affect LDL-C lowering.
A clinician-reviewed analysis of inclisiran safety, pharmacogenomics, and dosing considerations in Hispanic and Latino patients, with ethnicity-stratified ORION trial data and PharmGKB context.